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Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function,
present for >3 months, with implications for, among others, bone health. Advanced
stages of CKD have an increased risk of fragility fractures. Trabecular bone score (TBS)
is a relatively new gray-level textural parameter, which provides information on bone
microarchitecture and has been shown to be a good predictor of fragility fractures
independently of bone density and clinical risk factors. We aimed to review the scientific
literature on TBS and its utility along the CKD spectrum and in kidney transplant
recipients. In total, eight articles had investigated this topic: one article in patients with
reduced kidney function, two in patients on hemodialysis, and five in kidney transplant
recipients. In general, all the studies had shown an association between lower values
of TBS and reduced kidney function; or lower TBS values among the hemodialysis or
kidney transplant patients compared to healthy controls. Moreover, TBS was shown to
be a good and independent predictor of fragility fractures in patients with CKD or who
underwent kidney transplantation. TBS postulates itself as a valuable marker to be used
in clinical practice as an assessor of bone microarchitecture and fracture risk predictor
in these specific populations. However, evidence is to some extent limited and larger
follow-up case-control studies would help to further investigate the TBS utility in the
management of bone health damage and increased fracture risk in patients with CKD or
kidney transplant.
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INTRODUCTION
The Kidney Disease Improving Global Outcome (KDIGO) defines chronic kidney disease (CKD)
as abnormalities of kidney structure or function, present for >3 months, with implications for
health (1). CKD is classified based on the cause (i.e., diabetes or hypertension); glomerular
filtration rate (GFR) (stage 1: GFR ≥ 90 ml/min/1.73 m2, stage 2: GFR = 60–89 ml/min/1.73
m2, stage 3a: GFR = 45–59 ml/min/1.73 m2, stage 3b: GFR = 30–44 ml/min/1.73 m2, stage 4:
GFR = 15–29 ml/min/1.73 m2 and stage 5: GFR < 15 ml/min/1.73 m2); and albuminuria (normal
Shevroja et al. Trabecular Bone Score in Chronic Kidney Diseases
to mildly increased: <30 mg/g, moderately increased: 30–300
mg/g and severely increased: >300 mg/g). The presence of
a higher albuminuria in each stage of GFR carries a poorer
prognosis for the progression of CKD (1).
Among other health consequences, the declines in kidney
function cause changes in bone mineral metabolism which
weaken the skeletal system (2, 3). The CKD abnormalities
that are believed to independently or collectively alter bone
metabolism (remodeling or mineralization) are: secondary
hyperparathyroidism, abnormalities in 1,25-dihydroxyvitamin D
synthesis, phosphorus retention, chronic metabolic acidosis, and
elevated sclerostin and/or fibroblast growth factor 23 levels (4–8).
These abnormalities occur early in the course of CKD to become
almost universal in patients with advanced CKD (9, 10). All
together constitute a systemic mineral metabolism derangement
known as CKD-mineral and bone disorder (CKD-MBD), a term
suggested by KDIGO (3). It is well-recognized that advanced
stages of CKD (stages 3a−5) place individuals at particularly
high risk of fragility fractures, due to the alterations of bone
strength (11–13). This increase in fracture risk is attributable to
the combination of CKD-induced changes in bone and mineral
metabolism, and the classic fracture risk factors observed also
in the non-CKD population, such as: age, sex, previous fracture,
diabetes mellitus or glucocorticoid use (14). Fragility fractures
will eventually enhance the economic and social burden of CKD-
MBD (14).
Therefore, the evaluation of the risk of fracture in these
specific stages is very important. It is a silent agreement among
the bone health community that in the earlier stages of CKD
(stage 1–3), the fracture risk assessment is made as in the
general population; whereas by the time a patient progresses the
advanced stages (stages 4–5), bone metabolism derangements
become so dominant and the fracture risk increases so much that
the general population’s criteria may not be relevant anymore
(15, 16). Bone histomorphometry remains the gold standard to
evaluate bone abnormalities in the advanced CKD-MBD (3).
Nevertheless, as a costly and invasive technique, its routine
clinical use is very limited. Recent studies introduced enough
evidence that bone mineral density (BMD) as measured from
the dual-energy X-ray absorptiometry (DXA) scans, is a good
predictor of fractures in the spectrum of CKD stages 3a to stage
5 on dialysis (17–20), which allowed KDIGO for recommending
BMD measurement in their 2017 update (1). However, as in the
non-CKD patients, the relevance of BMD is limited due to its
overestimation in the presence of scoliosis, osteoarthritis at the
lumbar spine, vascular and/or joint calcifications. Moreover, it
has been suggested that both bone mass and texture need to be
assessed to provide an accurate assessment of fracture risk in
individuals with or without CKD (14). As BMD only measures
one factor, bone mass, providing no information on bone texture,
which is also adversely affected in CKD, it cannot be a stand-alone
risk factor for making management decisions (14).
Trabecular bone score (TBS) is a relatively new gray-
level textural parameter, which provides information on
bone microarchitecture (21). A homogenous microarchitecture
results in a higher TBS value, whereas a more heterogenous
microarchitecture results in a lower TBS value. TBS can be easily
measured from the lumbar spine DXA scans, which have been
previously obtained to measure BMD (21). One of the major
advantages of TBS is that it is not impacted by the presence of
overlaying calcifications due to degenerative changes in the bone.
In the general population, lower TBS values have been associated
with higher fracture risk independently of BMD and/or other
fracture clinical risk factors (22–25). It is now well-established
that TBS is an independent predictor of fracture risk, suggesting
its use in addition to BMD in fracture risk prediction (26). As
a result, TBS is now incorporated into FRAX, the most widely
used fracture risk assessment tool that uses a combination of
age, sex, clinical risk factors and femoral neck BMD (optional)
to predict the 10-years probability of major osteoporotic fracture
(hip, humerus, forearm and clinical vertebral fractures) (27).
Furthermore, studies have also demonstrated the ability of TBS
to predict fragility fractures in secondary osteoporosis, caused
by diabetes, primary hyperparathyroidism, rheumatoid arthritis,
adrenal incidentaloma, chronic kidney disease, or long-term
glucocorticoid therapy (28–31).
The aim of our study was to review the current scientific
literature on TBS and chronic kidney disease. We identified
studies that have investigated the ability of TBS to assess bone
health and to predict fracture risk along the CKD spectrum or
kidney transplantation.
Literature Search
Using both free text and MESH terms (trabecular bone
score, chronic kidney disease, hemodialysis and kidney
transplantation), a systematic search of the literature was
performed in PubMed database with no time and study type
limit, until January 2018. Abstracts were selected. References of
the retrieved articles were checked manually for further studies.
TBS in Patients With Reduced Kidney
Function
KDIGO defines the reduced kidney function as GFR < 60
ml/min per 1.73 m2 and normal kidney function as GFR ≥ 60
ml/min per 1.73 m2 (1). The reduced kidney function is further
classified in stages 3a−4, as stated above. Naylor et al. studied
the association of TBS with fracture risk in reduced kidney
function and examined whether this association differs from
that with normal kidney function, in the Canadian Multicenter
Osteoporosis Study (32). Adults (>40 years) with reduced kidney
function (n= 199) had a significantly lower mean TBS than those
with normal kidney function (n = 1.227; 1.275 vs. 1.297). The 5-
years probability of having a fragility fracture was higher among
individuals with reduced kidney function with TBS values below
the median (18.1%; 95% CI: 11.7–27.6%) than those with TBS
values above the median (6.2%; 95% CI: 2.8–13.3%). Moreover,
TBS showed to predict fracture independently of age, sex, FRAX
score, and BMD in both groups. These results suggest that as in
the general population, TBS may be a useful parameter to predict
fracture risk in patients with reduced kidney function.
TBS in Patients on Hemodialysis
Fractures occur more frequently in hemodialysis patients than
in the general population (33). For instance, patients receiving
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hemodialysis therapy have a 4-fold higher incidence of hip
fracture than the general population. Furthermore, hip fracture-
related mortality risk is two times higher with a GFR < 45 than
GFR ≥ 45 ml/min per 1.73 m2 (11, 34, 35). Scientific evidence
has very recently supported some fracture risk predictive value
of BMD in patients with end-stage renal disease (ESRD) (CKD
stage 4–5) and/or on dialysis (17–20). Nevertheless, there is a lack
of investigation of other bone parameters measured from DXA,
such as TBS in fracture risk prediction in ESRD patients. To the
best of our knowledge, two studies have evaluated TBS in this
group of patients.
Yavropoulou et al. studied the possible association of TBS
with other factors that reflect bone health in a cross-sectional
case-control study of 50 patients with ESRD undergoing chronic
hemodialysis (36). Participants were 23 women and 27 men
with a mean age of 62 ± 9.6 years. The control group were 52
healthy individuals (mean age = 59 ± 9.5 years) matched for
age, body mass index and gender. Patients on hemodialysis had a
significantly lower TBS than controls (1.11± 0.16 vs. 1.30± 0.13,
p < 0.001, respectively) and this difference remained significant
even after adjusting for age and serum levels of parathyroid
hormone, phosphate, alkaline phosphatase, and 25-OH-vitamin
D3. Furthermore, TBS was significantly lower among patients on
dialysis without osteoporosis than controls without osteoporosis,
and this was independent of BMD or other covariates (1.15 ±
0.181 vs. 1.32± 0.123, p= 0.001, respectively).
In the second study, Brunerova et al. aimed to contribute
further to the study of the utility of TBS in the ESRD patients
on dialysis (37). They assessed TBS in 59 patients (mean
age = 67.6 ± 13.1 years) on dialysis concluding that half of
them had severely impaired bone microarchitecture as assessed
by TBS. They additionally saw that there was a good correlation
between TBS and quantitative computed tomography (QCT),
which reflected the histomorphometric parameters. Thus, TBS
seems to be an effective and non-invasive indirect marker of
bone microarchitecture. Their data were too limited to further
investigate the utility of TBS in fracture risk prediction.
TBS in Kidney Transplant Recipients
Kidney transplantation has the best prognosis for patients with
severe end-stage renal failure (38). Improving the long-term
quality of life for these patients is an important matter. There
are contradictory results from studies that have investigated the
association of fracture risk with renal transplant. Risk factors,
such as duration of prior renal failure or dialysis, diabetes,
corticosteroids use have been associated, but not robustly,
with the increase in fracture risk after renal transplantation.
Nevertheless, the field lacks a well-established way to predict
fracture risk in these patients. The majority of studies on TBS and
CKD, actually are on the kidney transplant patients, as the most
vulnerable/exposed category of CKD patients to bone damage.
Naylor et al. investigated TBS in 327 adults kidney transplant
recipients (mean age = 45.3 ± 12.4 years) who received their
transplant in Manitoba, Canada; and compared it with 981
matched healthy individuals (mean age = 45.4 ± 12.3 years)
(39). Kidney transplant recipients had a significantly lower TBS
compared to controls (1.365± 0.129 vs. 1.406± 0.125, p< 0.001)
and a higher fracture probability as assessed by FRAX. During the
mean follow-up period of 6.6 years, 31 (9%) kidney transplant
recipients sustained one or more incident fragility fractures.
The recipients who sustained a fracture had a significantly
lower TBS than those who did not (1.301 ± 0.144 vs. 1.372
± 0.125, p = 0.003). TBS was able to discriminate between
recipients with and without a fracture (area under the curve
0.64; 95%CI: 0.53–0.74, p = 0.012). Furthermore, the kidney
transplant recipients with a lower TBS were less likely to remain
fracture-free (p = 0.017). Finally, lower TBS was associated
with fracture independent of FRAX (adjusted hazard ratio per
standard deviation decrease 1.55; 95%CI: 1.06–2.27).
Peres-Saez et al. performed a cross-sectional study to analyze
bone health outcomes in 53 ESRD patients (mean age = 55.8
± 12.1 years) at the time of undergoing kidney transplant
surgery (40). The control group was 77 healthy individuals (mean
age = 50.2 ± 16 years). TBS was measured in a mean time of
8 days after the kidney transplant surgery. TBS was higher in
the control group than in cases (1.20, interquantiles range IQR:
1.11–1.3 vs. 1.31, IQR: 1.19–1.43, p < 0.001). The duration of
dialysis before the transplant showed to have no effect on TBS
post-transplant.
Moreover, Perez-Saez et al. investigated TBS also in long-term
(mean follow-up time = 10 years) kidney transplant patients
in the same population with the previous study (41). The 40
cases (mean age = 63.8 ± 11.1 years) were matched with
77 healthy controls (mean age = 50.2 ± 16 years). TBS was
again lower among the cases than controls, but did not reach a
statistical significance (1.21 ± 0.14 vs. 1.30 ± 0.15, p = 0.072).
Interestingly, no differences in TBS or BMD between patients
on glucocorticoids and those glucocorticoids-free were found;
neither a correlation between TBS or BMD with the cumulative
glucocorticoid dose.
Luckman et al. followed 47 kidney transplant recipients
(mean age = 50.5 ± 13.7 years) for 12 months after their
kidney transplant (42). All patients underwent DXA scans at
baseline, 3, 6, and 12 months after the transplant surgery.
At baseline and at 12-months visit, 72 and 76%, respectively,
of the patients had normal BMD—which was in contrast to
TBS, as only 47 and 50%, respectively, of the patients had
TBS values that corresponded to a low fracture risk (TBS ≥
1.37). Nevertheless, 42% of the patients having normal BMD
values, were classified to the high fracture risk group by their
TBS values. TBS correlated to the high-resolution peripheral
quantitative computed-tomography (HR-pQCT) measures of
trabecular bone: trabecular thickness, density, stiffness and
failure load. Furthermore, despite having normal lumbar spine
BMD values, patients classified as high risk by TBS had
abnormal cortical and trabecular microarchitecture and lower
bone strength as assessed from the computational measures. In
general, older age and a history of pre-transplantation dialysis
were associated with a lower TBS at baseline; whereas male sex,
pre-transplant diabetes and elevated levels of bone resorption
marker (carboxy-terminal collagen crosslinks) were risk factors
for declines in TBS during the follow-up period.
Most recently, Aleksova et al. investigated TBS in 146 patients
(mean age = 48 ± 13 years) with progressed CKD (stage 5 on
dialysis) who had undergone a kidney (n = 114 patients) or
simultaneous pancreas kidney transplantation (n = 33 patients)
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(43). The mean TBS value was 1.345 ± 0.125 and TBS ≥ 1.31,
which indicates a lower risk of microarchitecture damage, was
present in 65% of the study population, whereas 15% of them had
a TBS < 1.23 which indicates a high risk for microarchitecture
damage. TBS did not significantly differ with sex, age or prior
dialysis duration. Patients with type 1 diabetes undergoing
simultaneous pancreas kidney transplantation had lower TBS
values than those undergoing only kidney transplantation.
Furthermore, prevalent non-vertebral fractures were significantly
associated with lower TBS values (p = 0.023). Low TBS values
(≤1.31) were a good predictor of non-vertebral fractures, but
not of combined vertebral and non-vertebral fractures. Even after
adjusting for the relevant covariates, TBS remained significantly
associated with prevalent non-vertebral fractures independently
of femoral neck BMD and FRAX (odds ratio per standard
deviation decline in TBS= 1.54; 95%CI: 1.03–2.31; p= 0.036).
DISCUSSION
To the best of our knowledge, this is the first literature review
of the utility of TBS in bone health assessment and fracture risk
prediction in patients with chronic kidney disease undergoing
dialysis or kidney transplantation. In general, these studies are
in line with each other in associating lower TBS values with
an impaired kidney function along the CKD spectrum and
among the kidney transplant recipients; and concluding that TBS
can predict fracture risk independently of bone density in this
population.
The lack of a well-established strategy to assess bone health
and fracture risk in patients with end-stage renal disease is
an important matter of bone community. The presence of
bone health deterioration in these patients could have possible
therapeutic implications which could decrease the risk of having
a fragility fracture and furthermore, improve their prognosis.
The current gold standard method to assess bone deterioration,
bone biopsy, is an invasive technique with a limited availability
(3). Thus, research has been focused on the investigation
of non-invasive measurements of bone strength that would
predict fractures in this population. Recent studies concluded
that the utility of BMD, one of the bone parameters used
in the general population to predict fragility fractures and
assess bone health, is valuable in the management of ESRD
patients with MBD (17–20). As in the general population, BMD
measurement alone cannot always estimate the severity of bone
disease (14). Hence, the investigation of the utility of TBS, as
another non-invasive bone parameter that have shown to be
independent of BMD, in this population, has gained special
attention.
In patients with ESRD on hemodialysis, TBS suggests that
a significant deterioration of bone quality might be present,
independent of bone mass and other biochemical changes in
ESRD, postulating itself as a valuable marker in assessing bone
quality in these patients (36, 37). Nevertheless, the small sample
sizes of the current studies on this topic, could not allow the
full investigation of TBS predictive value in the risk of fragility
fractures.
The majority of studies on TBS and CKD are on kidney
transplant recipients, as an exposed group to ESRD and other
causes of osteoporosis, such as glucocorticoids use. They have
robustly shown that patients who had undergone a kidney
transplant had a lower TBS than matched controls, suggesting
of a remained bone microarchitecture alteration after the
kidney transplant (39, 40, 42, 43). Potential mechanisms that
might explain this bone loss include the damage caused from
the pre-transplant ESRD; the exposure to agents, such as
glucocorticoids after the transplant, which has its major effect
on bone health, affecting its microarchitecture as well; and post-
operative immobility followed by increased physical activity due
to improved health status (3, 44–48). Nevertheless, the only
study with a long-term follow-up period of the patients, 10 years
after their kidney transplant surgery, demonstrated an almost
complete recovery of bone quality as measured from TBS (41).
Interestingly and contrary to what was expected, this study also
showed no differences in bone assessments among patients who
were on glucocorticoids and those whowere not—suggesting that
further investigation of the long-term effect of glucocorticoids on
bone in this population is needed. Furthermore, TBS was shown
to be a good fracture risk predictor in this patients’ category.
The wide range of TBS values in patients with reduced
kidney function (32), on hemodialysis (36, 37) and kidney
transplant recipients (38–43) does not allow us to speculate on
an association between the deterioration of renal function and
decline in TBS. Nevertheless, the results of the studies reported
in this review cannot be compared due to the differences in
characteristics, such as age or body mass index, and the DXA
devices used in the studied populations. The exploration of
this relationship and the suggestive TBS thresholds to be used
in clinical practice for this patients’ category in larger follow-
up case-control studies would help to further elaborate on this
matter.
In overall, current evidence suggests that the management
of bone health alterations and fracture risk assessment among
patients with CKD and those after kidney transplantation, might
be similar to that of the non-CKD population. The studies
robustly show a damage of bone microarchitecture as measured
by TBS (and consistent with findings from other technics, such as
HR-pQCT), and confirm the ability of TBS to predict the risk of
fragility fractures in this population. Based on these insights, TBS
assessment is reasonable in the fracture risk prediction in this
population. Additional investigation on the TBS thresholds in
this population will eventually contribute to the improvement of
their clinical management.
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